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1. Introduction 
Estrogen plays a major part in the regulation of cell proliferation and survival, controlling 
female physiology, reproduction and behaviour (Musgrove and Sutherland, 2009). It 
however assumes a more malevolent role in its association with breast cancer pathogenesis. 
Consequently, therapies have been designed to block the actions of estrogen mediated 
through its receptors (ERǂ and ERǃ), or to simply reduce its levels in the body (Zilli et al., 
2009). Since Beatson (1896) first introduced ovariectomy over a century ago as the first 
therapeutic modality to reduce the adverse effects of estrogen, endocrine therapy has 
developed into the cornerstone of breast cancer treatment for those 60-70% of patients 
whose tumours over-express ER and/or progesterone receptor (PR) (Massarweh and Schiff, 
2007; Zilli et al., 2009). For three decades, selective estrogen receptor modulators (SERMS), 
predominantly tamoxifen, have proved to be effective agents for the suppression of breast 
cancer growth in both early and advanced disease (Normanno et al., 2005). Tamoxifen has 
significantly improved the quality of life and survival of many patients with metastatic 
disease, as well as displaying prophylactic benefit, particularly in women with ductal 
carcinoma-in situ (Fisher et al., 1999).  
However, about half of ER+ patients with advanced disease and nearly all patients with 
metastatic disease fail to respond to first-line tamoxifen therapy. About 40% of patients 
receiving tamoxifen as adjuvant therapy experience tumour relapse and die from their 
disease, and a third of women treated with tamoxifen for 5 years develop recurrent disease 
within 15 years (Normanno et al., 2005). The introduction of pure estrogen antagonists such 
as fulvestrant, to overcome the apparent disadvantage of tamoxifen with its partial agonist 
properties, did not resolve the resistance problem (Osborne and Schiff, 2011). Second line 
therapy with other endocrine agents designed to inhibit peripheral extra-gonadal synthesis 
of estrogen in postmenopausal women produces some beneficial effects but for the most 
part serves merely to delay onset of endocrine resistance (Massarweh and Schiff, 2007). This 
refractiveness to continued administration of anti-estrogens and aromatase inhibitors poses 
a significant therapeutic problem that has been addressed by a large number of studies. 
Several theories have been proposed to explain this phenomenon, based on observations 
made with a variety of in vitro cellular models (Normanno et al., 2005). The consensus 
opinion seems to be that whereas de novo resistance is most likely due to low levels of ER 
expression, acquired resistance is predominantly the consequence of an attenuated response 
to other peptide growth factors that normally play a subsidiary role in cell proliferation. 
www.intechopen.com
 Breast Cancer – Focusing Tumor Microenvironment, Stem Cells and Metastasis 
 
452 
These molecules exert their action through a variety of trans-membrane receptors that 
possess intrinsic tyrosine kinase activity. Fig 1 depicts the various potential influences that 
govern the behaviour of breast cancer cells.  
 
 
 
Fig. 1. Factors affecting growth and proliferation of breast cancer cells. Breast epithelial cells 
are subject to various influences that can either promote or inhibit cellular activity. (A) 
Endocrine stimulation by a variety of hormones, most significantly estrogen, promotes long 
term effects. (B) Autocrine stimulation involves, under various conditions, the production 
and secretion of a number of peptides that act back on the producer cell to modify its 
activity through membrane bound receptors that frequently possess intrinsic tyrosine kinase 
activity which initiates a signalling cascade that terminates in the action of transcriptional 
regulators to modify gene expression. (C) Paracrine stimulation is effected by the action of 
mediators which include the listed peptide growth factors as well as others originating from 
myoepithelia (in the normal breast) and stromal elements that include fibroblasts and 
macrophages in tumours. All of these pathways have been found to operate both in vitro (in 
tumour-derived cell lines) and in vivo, but their relative contributions vary considerably in 
both cases and may be influenced not only by biological heterogeneity but also by 
therapeutic interventions. 
It is also a general experience that endocrine resistance is associated with increased 
aggressiveness and frequent metastasis (Hiscox et al., 2007), characteristics that more often 
typify ER-ve tumours. Identification of ligands, receptors and downstream signaling 
molecules with increased activity in the resistant phenotype, both in cell culture and in 
tumour biopsies, has highlighted a bewildering collection of molecules that may play a 
direct causative role, be a consequence or simply innocent bystanders in the progressive 
cellular change towards endocrine independence. For the purposes of therapeutic 
discrimination, attempts have been made to reduce this plethora, generated principally by 
microarray analyses (eg Charafe-Jauffret et al., 2006 ; Luqmani et al., 2009; Al Saleh, 2010) to 
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a manageable number, and given the designation of ‘gene signature’ by virtue of selectively 
circumscribing a particular sub-group of patients.  
In a separate scenario, new insights have been gained into our understanding of cell 
differentiation from studies that have demonstrated that epithelial cells have the potential to 
trans-differentiate into mesenchymal cells (epithelial to mesenchymal transition: EMT) and 
vice versa (mesenchymal to epithelial transition: MET). Many recent reports have indicated 
that this process, which was previously observed during transition between developmental 
stages, is synonymous with the process of tumour metastasis. Both processes share similar 
pathways of activation. Our recent data (Luqmani et al., 2009; Al Saleh, 2010; Al Saleh et al., 
2011a) suggests that there may also be causal links between the development of endocrine 
resistance and the onset of EMT. In this report we summarise the molecular pathways of ER 
activity, the mechanisms proposed to account for resistance and finally review the evidence 
for the above hypothesis.  
2. Mechanisms of estrogen receptor induced cell proliferation 
ERǂ and ERǃ are transcribed from distinct genes located on separate chromosomes (6 and 
14, respectively) (Green et al., 1986; Kuiper et al., 1996). These receptors differ in their tissue 
distribution, with ERǂ being highly expressed in the pituitary gland, ovaries (thecal and 
interstitial cells), uterus, liver, kidneys, adrenals and the mammary glands while ERǃ is 
found mainly in the prostate, bone, ovaries (granulosa cells), lungs and in various parts of 
the central and peripheral nervous system (Emmen et al., 2005; Kuiper et al., 1997). 
Nevertheless, ERǂ and ERǃ do overlap in their expression in some tissues (Zilli et al., 2009). 
More importantly, the two receptors have different roles in breast development. Only ERǂ 
appears to be essential for ductal growth although both receptors are present in the breast. 
ERǂ-knockout mice show very little growth of mammary ducts, while ERǃ-knockout mice 
develop a normal mammary gland with regular ductal branching (Förster et al., 2002; 
Lubahn et al., 1993). This suggests that ERǃ might be exerting pro-differentiative and anti-
proliferative functions. In addition, increased ERǂ/ERǃ ratio in breast cancer as compared 
with benign tumours and normal tissues suggest that ERǂ is most closely associated with 
breast cancer pathogenesis, while ERǃ can protect against the mitogenic activity of estrogens 
in pre-malignant lesions (Roger et al., 2001; Shaw et al., 2002). It has even been suggested 
that the estrogen-induced proliferation of ER+ breast cancer cells can be inhibited by ERǃ 
over-expression (Ström et al., 2004; Williams et al., 2008). Thus ERǂ remains the main focus 
of attention in studies on breast cancer. Unless otherwise specified, ‘ER’ in this review will 
refer to ERǂ.  
In what is now referred to as the nuclear or genomic action of ER, binding of estrogen 
induces activation of the receptor by initiating its dissociation from cognate heat shock 
proteins, and leads to conformational changes, dimerisation and autophosphorylation 
(Osborne & Schiff, 2005). The activated ER binds to estrogen response elements (EREs) 
located in the promoter regions upstream of estrogen-regulated genes. Frasor et al., (2003) 
observed from microarray analysis of gene expression in MCF-7 cells that about 70% of such 
estrogen-regulated genes were actually down-regulated following treatment with estradiol. 
Many of these genes are transcriptional repressors, or genes with anti-proliferative or pro-
apoptotic function. On the other hand, there is increased expression of genes inducing cell 
proliferation and survival. Up-regulation of gene expression is mediated through two 
domains; activating function-1 (AF-1) and activating function-2 (AF-2). AF-1 is a hormone 
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independent domain located at the N-terminus of the receptor with its function regulated by 
phosphorylation. AF-2 is the site where ligand-binding actually occurs and is therefore 
hormone dependant. Almost all gene promoters are activated through both AF-1 and AF-2, 
though some are activated independently by AF-1 or AF-2 (Gronemeyer 1991; Osborne et 
al., 2001). Subsequent to formation of the ER-ligand complex, binding of co-regulatory 
molecules such as nuclear-receptor co-activator 1 (NCOA1 or SRC1), NCOA2 (TIF2) and 
NCOA3 (AIB1, TRAM1, RAC3 or ACTR) (Leo & Chen 2000; McKenna et al., 1999) enhance 
the transcriptional activity of ER accompanied by increased activity of histone-
acetyltransferase (HAT) at the promoter site. Other co-regulatory molecules can also partly 
suppress the transcriptional activity of ER by recruitment of histone-deacetylase complexes 
such as nuclear-receptor co-repressor 1 (NCOR1) and NCOR2 that influence ER-induced 
transcription (Chen & Evans, 1995; Horlein et al., 1995). Several of these groups of molecules 
have been reported to have prominent roles in cancer. AIB1 (SRC-3) is over-expressed in 
almost two thirds of all breast cancers and associated with a shorter disease-free survival in 
patients receiving tamoxifen as adjuvant treatment (Osborne et al., 2003). In untreated 
patients, high levels of AIB1 were associated with improved outcome, consistent with 
studies that suggest the possibility of an association between an enhanced agonistic effect of 
tamoxifen and the high levels of co-activators. However, ER can also co-operate with 
FOS/JUN and bind with other transcription factors such as AP-1 (activator protein-1) and 
SP-1 (specificity protein-1) at their specific sites on DNA (Kushner et al., 2000; Ray et al., 
1997; Safe 2001) commonly designated as serum response elements (SRE). 
In addition to its classical mode of action through a nuclear-located receptor, estrogen has 
also been reported to interact with membrane associated receptors, leading to a more rapid 
reaction than would be expected from a transcriptionally mediated response, such as 
initiation of cAMP production (Rosner et al., 1999; Zivadinovic et al., 2005) and activation of 
intrinsic kinases present in other plasma membrane receptors such as insulin-like growth 
factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR) and ERBB2 (Bunone et 
al., 1996; Campbell et al., 2001; Font de Mora & Brown 2000) as well as receptors for 
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF) and hepatocyte growth factor (HGF). It has been suggested that 
interaction of SERMs including tamoxifen with such membrane associated receptors may be 
responsible for their agonist behaviour. There is however much controversy over this issue, 
with other studies discounting the involvement of such postulated receptors as G protein-
coupled receptor as targets of estrogen action (Otto et al., 2008). However this may be, any 
non-genomic interactions of estrogen would depend on the levels of the above-mentioned 
kinases, and they will likely be modest in ER+ breast cancer cells that express low levels of 
tyrosine kinase receptors such as EGFR and ERBB2 (Normanno et al., 2005). 
Ligand independent activation of ER can occur via the downstream signaling cascades 
transmitted through membrane receptor tyrosine kinases such as EGFR, ERBB2, and IGF1R 
In particular. MAPK/ERK, PI3K/AKT, p90RSK and p38 MAPK pathways can specifically 
activate ER at key positions (serine 118 and 167 and threonine 311) in the AF-1 domain and 
in other domains (Bunone et al., 1996; Campbell et al., 2001; Joel et al., 1998; Kato et al., 
1995). Expression of ligands and receptors such as transforming growth factor-ǂ (TGFǂ), 
IGF1 and IGF1R can be increased by estrogen and those can then initiate signalling while 
expression of other receptors such as EGFR and ERBB2 is decreased by estrogen signaling 
(Kushner et al., 2000; Massarweh et al., 2008; Umayahara et al., 1994; Vyhlidal et al., 2000; 
Yarden et al., 2001). In addition, activation of the PI3K/AKT and the p42/44 MAPK 
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pathways by these receptors down-regulates the expression of ER and PR causing reduction 
in estrogen dependency while activating the transcriptional function of ER, which suggests 
a contribution of this cross talk to the relative resistance to endocrine therapies in tumours 
with amplified ERBB2 expression (Bayliss et al., 2007; Brinkman and El-Ashry, 2009; 
Creighton et al., 2010; Lopez-Tarruella and Schiff, 2007). 
The two types of ER actions, genomic and non-genomic, are not mutually exclusive and do 
overlap. For example, ER induces the expression of transcripts for both TGFǂ and 
amphiregulin (Normanno et al., 1993; Saeki et al., 1991) which can both bind and activate 
EGFR resulting in activation of MAPK and AKT signaling which are also activated by direct 
interaction with ER (Salomon et al., 1995). ER binding to membrane caveolin-1 leads to the 
activation of specific G proteins resulting in the activation of SRC and in turn of matrix 
metalloproteinases that cleave transmembrane precursors of the EGFR ligand, heparin 
binding-EGF (HB-EGF) (Levin, 2003; Razandi et al., 2003). Fig 2 illustrates the major 
identified downstream events involving ER activation. 
3. Mechanisms of endocrine resistance  
It should be noted that most tumours are heterogeneously composed and a biphasic 
response to treatment could reflect the survival and eventual clonal outgrowth of an 
intrinsically resistant minor sub-population. 
3.1 Alterations in ER expression or function 
Since all endocrine therapies target ER, the expression of the latter is the main predictor of 
the outcome of such therapies. The de novo resistance is clearly caused by the lack of ER 
expression which can be due to histone deacetylation (Parl, 2003) or associated with 
aberrant methylation of ER CpG islands that deactivates chromatin (Ottaviano et al., 1994; 
Weigel & deConinck, 1993 ). Interestingly, ER expression can be restored in ER-ve breast 
cancer following co-treatment with DNMT1 and HDAC inhibitors (Robertson et 
al., 2000; Rountree et al., 2000; Yang et al., 2001).  
It was initially thought that acquired resistance might be due to missing or non-functional 
variants of ER. However, only 17–28% of patients with acquired endocrine resistance lack ER 
expression (Gutierrez et al., 2005; Johnston et al., 1995 ). Furthermore, approximately 20% of 
tamoxifen-resistant patients will eventually respond to second-line treatment with 
aromatase inhibitors or fulvestrant (Howell et al., 2005; Osborne et al., 2002). Although a 
number of exon-deleted receptor isoforms have been described, their frequency is 
insufficient to account for resistance.  
Furthermore, these mutations have been detected in ER-ve tumours (Herynk & Fuqua 2004). 
A mutation that results in a hypersensitive receptor that shows enhanced binding of co-
activators in the presence of low estrogen levels (a single amino acid substitution changing 
lysine 303 to arginine) was found in 20 of 59 hyperplastic breast lesions (Fuqua et al., 2000). 
However, the role and frequency of such mutations in primary breast carcinomas and their 
relation to endocrine resistance needs to be explored in a larger number of patients.  
Patients carrying inactive alleles of cytochrome P450 2D6 (CYP2D6) (approximately 8% of 
Caucasian women) fail to convert tamoxifen to its active metabolite, endoxifen (4-hydroxy-
N-desmethyl-tamoxifen), and are consequently less responsive to tamoxifen, which is 
considered to be a significant factor in resistance to therapy (Hoskins et al, 2009). The 
baseline levels of endoxifen are elevated in patients carrying the wild-type CYP2D6 and who 
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Fig. 2. Proposed cellular mechanisms mediated through the estrogen receptor. 1. Classical 
genomic mode of action, in which estrogen binds to an inactive ER complex, causing 
dissociation from heat shock and other cognate proteins, receptor dimerisation and 
phosphorylation (P). This can then interact directly with estrogen response elements (ERE) 
on target genes in concert with histone acetyl transferase (HAT) and several other co-
activators (coA) or by association with the ubiquitous transcriptional factors FOS/JUN and 
with NCOA1 and AIB1 co-activators at API/SPI sites termed serum response element (SRE). 
2. Cytoplasmically located ER can be phosphorylated by the action of AKT, SRC and 
ERK/MAPK serine/threonine kinases, downstream of signalling events initiated by various 
growth factors’ interaction with their respective tyrosine kinase containing receptors and 
mediated through RAS or PI3K. This ligand- independent activated receptor can initiate 
transcription through the SRE. 3. Binding of estrogen to membrane–associated ER may 
induce assembly of complexes with either PI3K/FAK/SRC leading to activation through 
ERK of the transcriptional activator NCOA3 or with PELP1/SRC resulting in up-regulation 
of mTOR and NFKB through AKT. These mediate an action through other transcriptional 
response elements (TRE) on a variety of target genes without involving direct interaction of 
ER with chromatin. The latter mechanisms are referred to as the non-genomic pathways, 
that are postulated to explain those observed effects of estrogen which are too rapid to be 
accounted for by mechanism 1. Further ‘crosstalk’ between ER and RTKs may involve 
participation of PELP1. 
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had low levels of the metabolite when co-treated with paroxetine, a selective serotonin re-
uptake inhibitor (prescribed to alleviate tamoxifen-associated hot flashes) that can inhibit 
CYP enzymes. Heterozygous patients showed a better outcome when treated with 
tamoxifen, as compared with untreated patients suggesting a role for cytochrome 
P450 enzyme variants in regulating the response to tamoxifen (Wegman et al., 2005).  
The presence of ER variants was also hypothesized to have a role in endocrine resistance. A 
reduced response to endocrine therapy has been associated with the presence of a new 
truncated variant of ER, ER36, in addition to the full-length receptor (Shi et al., 2009).  
3.2 Estrogen receptor β 
It has been reported that ERß transcript levels were about 2-fold higher than those of ERǂ in 
tamoxifen-resistant as compared with tamoxifen-sensitive patients (Speirs et al., 1999) and 
that ERß bound to tamoxifen, raloxifen or the anti-estrogen ICI 164 384, increased 
transcription of AP-1-dependent genes (Paech et al., 1997). Other studies show that ERǃ has 
a negative effect on ERǂ-promoted transcription (Hall & McDonnell 1999; Pettersson et 
al., 2000) or no correlation with response or resistance to endocrine treatment (Cappelletti et 
al., 2004). Development of antibodies distinguishing between the ER types and their variants 
has led to identification of responses in ERǃ+ve but ERǂ-ve cancers and a potential role for 
the carboxy-terminally truncated variants of ERǃ (ERǃ2 and ERǃ5) in tamoxifen 
responsiveness (Honma et al., 2008; Murphy and Watson, 2006). In addition to ERǃ, the 
oestrogen-related receptor ERRǄ was found to be over-expressed and mediated tamoxifen 
resistance in lobular invasive breast cancer models (Riggins et al., 2008).  
3.3 Adaptation to estrogen withdrawal 
Breast cancer cells can acquire a state of hypersensitivity to estrogen that renders them 
resistant to endocrine therapy. MCF7 cells cultured in estrogen-free medium to produce 
long-term estrogen deprived cells (LTED) mimics the effects of ablative endocrine therapy 
(Santen et al., 2003) and produces cells that are highly sensitised to substantially lower 
concentrations of estrogen as compared with wild-type MCF-7 cells (Masamura et al., 1995). 
Growth factor signalling and ER expression was significantly higher in these cells. 
Treatment with estrogen resulted in rapid association of ER and phosphorylation of SHC, 
an adaptor protein involved in tyrosine kinase receptor signalling, and increased activation 
of both SRC and the RAS/RAF/MEK/MAPK signalling pathways (Song et al., 2002a,b; 
Song et al., 2004). Exposure of these cells to fulvestrant blocked MAPK activation indicating 
that this pathway may be a downstream effector of the ER non-genomic pathway (Santen et 
al., 2003; Song et al., 2002a,). However, a high AKT and MAPK level in LTED cells was 
associated with increased resistance to endocrine therapy and a worse outcome.  
In another version of MCF7 LTED cells, enhanced transcriptional activity of ER was 
associated with increased activation of growth factor pathways that in turn trans-activate ER 
(Johnston & Dowsett, 2003). After prolonged culture in the absence of estradiol, the ER in 
these cells functions independently from exogenous estradiol, which was suggested to be 
due to a super-sensitivity of LTED to residual estrogen present in the medium (Chan et 
al., 2002; Martin et al., 2003). These cells also showed increased levels of phosphorylation of 
ER at serine 118, a known target for several intracellular kinases. Furthermore, IGF-1R and 
ERBB2 signalling was significantly increased in these cells concurrently with increased 
MAPK activation. Interestingly, the phosphorylation of ER at serine 118 was blocked by 
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MAPK or EGFR/ERBB2 blockade but not by blocking MEK/MAPK or PI3K/AKT 
signalling, indicating that additional kinases might be involved in this hypersensitive state.  
Nicholson et al., (2004) also developed an MCF7 cell line (MCF-7X cells) that is resistant to 
estrogen withdrawal but not hypersensitive to it. These cells could be growth inhibited by 
fulvestrant, implying that the ER pathway is still involved in their proliferation. However, 
the PI3K/AKT pathway was demonstrated to be the main factor promoting their growth 
without the involvement of EGFR/ERBB2 or IGF-1R signalling, suggesting that the 
adaptation to estrogen withdrawal can occur in the absence of increased sensitivity to 
estrogen and does not require activation of classical growth factor receptors. 
3.4 Estrogen receptor and co-regulators 
Since ER action is mainly controlled through transcriptional factors and co-regulator 
molecules, it seems likely some of these may be implicated in endocrine resistance. For 
example, increased AP1 and NFKB transcriptional activity has been associated with 
endocrine resistance (Johnston et al., 1999; Zhou et al., 2007). And similarly when ER co-
activators are over-expressed or phosphorylated. For example, NCOA3 (A1B1 or SRC3) 
over-expression leads to constitutive ER-mediated transcription, which confers resistance 
both in vitro and in xenograft models and is associated with reduced responsiveness to 
tamoxifen in patients (Ali & Coombes, 2002; Osborne et al., 2003; Ring & Dowsett, 2004). 
Another ER co-activator associated with resistance is PELP1 (Fig 2) which is a cytoplasmic 
scaffold protein that modulates ER interaction with SRC, leading to activation of SRC and 
the ERK family kinases and also promotes oestrogen activation of PI3K (Gururaj et al., 2006). 
Interestingly, ER cytoplasmic complex composed of ERǂ, PI3K, SRC and focal adhesion 
kinase (FAK; also known as pTK2) is formed as a result of the transient methylation of ER at 
R260 by protein arginine N-methyltransferase 1 (pRMT1). This complex activates AKT and 
could confer resistance to endocrine therapy but this methylation event which is frequent in 
breast cancer has yet to be linked to resistance (Le Romancer et al., 2008). 
3.5 Growth factor receptor pathways  
Perhaps the most important factors that affect the response to endocrine therapy are those 
that can modulate alternative proliferation and survival in the tumours in which the ER 
signalling pathway is effectively inhibited. These alternative growth pathways can do so by 
the establishment of a bidirectional cross talk with ER signalling. These pathways will act as 
ER-independent drivers of cancer proliferation and survival and are involved in both de 
novo and acquired resistance (Normanno et al., 2005). Increased expression of EGFR, ERBB2 
and IGF1R along with their downstream components such as ERK and PI3K can modulate 
tamoxifen resistance (Faridi et al., 2003; Hutcheson et al., 2003; McClelland et al., 2001). 
ERBB2 has been reported to be over-expressed in association with down regulation of the X-
linked tumour suppressor forkhead box p3 (FOXP3) and the zinc finger transcription factor 
GATA4 (Hua et al., 2009; Zuo et al., 2007). Other factors that might affect ERBB2 expression 
are the presence of the paired-domain transcription factor PAX2 and the ER co-activator 
NCOA3 which compete for binding and regulating ERBB2 transcription and, in turn, 
responsiveness to endocrine therapy. However, like GATA4 and FOXP3, PAX2 was also 
shown to be down-regulated in tamoxifen resistant breast cancers in the presence of NCOA3 
and an over-expressed ERBB2 (Hurtado et al., 2008). The SRC substrates BCAR1 and BCAR3 
have both been reported to elicit endocrine resistance in vitro (Dorssers et al., 1993). BCAR1 
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binds and activates SRC leading to phosphorylation of EGFR and the signal transducer and 
activator of transcription 5B (STAT5B) (Riggins et al., 2007). On the other hand, BCAR3 is 
believed to activate RAC and p21-activated kinase 1 (pAK1), which is a mediator of 
endocrine resistance itself through ER phosphorylation, and through the activation of SRC 
in association with BCAR1 (Cai et al., 2003; Rayala et al., 2006; Riggins et al., 2003; van 
Agthoven et al., 1998).  
The de-regulation of several growth pathways including EGFR, ERBB2 and IGF1R are 
implicated in endocrine resistance (Faridi. et al., 2003; Miller et al., 2009). Many events might 
trigger this de-regulation such as activating mutations in PIK3CA and loss of heterozygosity 
or methylation of PTEN, activation of AKT, over-expression of ERBB2 and activation of 
IGF1R and ERBB3 following the loss of PTEN (Arpino et al., 2008; Miller et al., 2009; Riggins 
et al., 2007). However, following de-regulation of these pathways acquisition of endocrine 
resistance might be effected by a number of possible activities as summarised by Musgrove 
& Sutherland, (2009): “decreased ER expression mediated by ERK activation; loss of ER-
mediated repression of EGFR and ERBB2 and consequent activation of mitogenic signalling 
cascades; ligand-independent activation of ER or its co-activators through phosphorylation; 
up-regulation of key cell cycle regulators, for example MYC and the D and E-type cyclins, 
through constitutive activation of mitogenic signalling pathways; and the inhibition of 
apoptosis through constitutive activation of survival signalling”. 
3.6 Cell cycle signalling molecules 
In order for cancer cells to bypass the inhibition of cell proliferation elicited by endocrine 
agents, one would expect down-regulation of effector molecules involved in the induction of 
apoptosis while those involved in proliferation, especially during G1 phase, are up 
regulated. Over-expressed cell cycle regulators include MYC, cyclin E1, cyclin D1, cyclin 
D1b, as well as p21 and p27, and a de-activated RB gene (Prall et al., 1998; Wang et al., 2008). 
Over-expression of MYC and cyclin D1 leads to an abundance of CDK complexes that are 
directly associated with increased cellular proliferation and/or relief of the inhibitory effects 
of the negative cell cycle regulators p21 and p27, a phenomenon that is also achieved 
through activation of ERBB2, AKT and SRC (Caldon et al., 2009; Chu et al., 2008; Hui et al., 
2002; Perez-Tenorio et al., 2006). Cyclin D1 can also interact with several transcription 
factors including ER and STAT3 (Coqueret et al., 2002). Tamoxifen actually enhances the 
binding of cyclin D1 to ER at the expense of STAT3, hence activating both transcription 
factors and consequently establishing endocrine resistance (Ishii et al., 2008). Other 
important molecules are those involved in apoptosis. In particular, the pro-apoptotic 
molecules such as BIK (BCL2-interacting killer) and caspase 9 are down regulated in 
endocrine resistant cancers while those which are considered as anti-apoptotic molecules 
such as BCL-XL and its second messenger ceramide, are up regulated (Mandlekar et al., 
2001; Riggins et al., 2005) . The expression of these molecules is also affected by signalling 
through PI3K/AKT, TNF, IFN and NFKB.  
4. Epithelial mesenchymal transition  
The phenomenon of epithelial cells undergoing a transition towards a mesenchymal 
phenotype was first identified as programmed events occurring during embryonic 
developmental processes (Greenberg & Hay, 1982). Since then EMT has since been described 
in various pathological conditions. During the process of cancer metastasis, a minority of 
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epithelial cells lose their apico-basal polarity, detach from adjacent cells, scatter and acquire 
increased motility and are able to invade into the extracellular matrix with subsequent 
penetration into the vasculature. This process is facilitated by a morphological 
transformation into a fibroblastoid structure that has all the hallmark features of EMT, Both 
processes share remarkable similarities, with characteristic phenotypic changes. These 
include the loss of cell-cell adhesion as a result of reduced E-cadherin in adherens junctions, 
occludins (OCLN) and claudins (CLDN) in tight junctions and desmoplakin (DSP) in 
desmosomes and down regulation of epithelial cytokeratins (KRT8, KRT18, and KRT19) and 
up-regulation of mesenchymal proteins most notably vimentin (VIM) and fibronectin and 
sometimes alpha smooth muscle actin (ACTA2) along with many other changes.  
Fig 3 depicts the changes occurring during EMT. Multiple molecular mechanisms underlie 
EMT initiation and its reversal process, MET, which cancer cells are thought to undergo at 
sites where they form metastases, in order to re-establish cohesive colonies and initiate neo-
vascularisation.  
 
 
Fig. 3. Epithelial to mesenchymal transition. Loss of epithelial characteristics and breakdown 
of tissue architecture through dissolution of cell-cell junctions and loss of apico-basal 
polarity by detachment from the basement membrane can be initiated through a variety of 
diverse cellular insults which lead to transformation into a cell type that displays 
mesenchymal–like features. At a molecular level there is a certain uniformity of changes. 
Cells that have lost ER function and consequently acquired endocrine independence, in this 
case by shRNA- induced down-regulation (Al Saleh, 2010), show both the morphological 
appearance as well as the phenotypic changes that are characteristic of cells undergoing 
EMT. Several differences are indicated between MCF7 and pII cells that parallel those seen 
during EMT. 
www.intechopen.com
 Endocrine Resistance and Epithelial Mesenchymal Transition in Breast Cancer 
 
461 
The transformation of epithelial cells into a mesenchymal-like form requires the 
participation of a complex network of both extra- and intra-cellular signals., Amongst the 
many identified are TGFǃ, HGF, FGF, EGFR family members, IGF1 and 2, and PDGF 
(Thiery et al., 2002). An array of embryonic transcription factors such as the homeobox 
protein GOOSECOID (GSC), TCF3 (E47), the zinc-finger proteins SNAIL1 and SNAIL2 
(previously SLUG), the basic helix-loop-helix protein TWIST1, the forkhead box proteins 
FOXC1 and FOXC2 , and the zinc-finger E-box-binding proteins ZEB1 and ZEB2 (SIP1) , are 
generated by the activity of these growth factor pathways, each of which is capable, on its 
own, of inducing an EMT. 
There is increasing evidence of extensive crosstalk between these molecules, permitting the 
formation of an extensive signalling network responsible for establishing and maintaining a 
mesenchymal phenotype. (Moreno-Bueno et al., 2008; Peinado et al., 2007). In addition, 
some of these transcriptional activators such as TWIST are pivotal factors in overcoming 
cellular senescence (Ansieau et al., 2008) and in generating tumourigenic cancer stem cells 
(Mani et al., 2008). Interestingly, EMT-inducing transcription factors also confer stem cell 
characteristics on epithelial cells. For example, the receptor KIT which is an important factor 
for maintaining the stem cell state in the haematopoietic system has been shown to induce 
SNAIL2 expression in both mice (Perez-Losada et al., 2002) and humans (Sanchez-Martin et 
al., 2002). Many of these transcription factors exert repressive functions by binding to 
conserved E-box sequences in the promoter regions of such critical genes as CDHI (Gilles et 
al., 2003; Pieper et al., 1992). 
4.1 Transforming Growth Factor β 
TGFǃ can independently promote an EMT phenotype in mouse mammary epithelial cells 
(Thuault et al., 2006; Waerner et al., 2006). This cytokine induces EMT by both SMAD-
dependent and independent signalling events (Berx et al., 2007; Das et al, 2009; Santisteban 
et al., 2009). In advanced disease, TGF-ǃ can stimulate invasion and metastasis of tumours 
that have become TGF-ǃ insensitive which can be inhibited by ectopic expression of 
dominant negative TGF-ǃ receptors (Ozdamar et al., 2005). TGF-ǃ1 ligand activates a 
heteromeric receptor of two transmembrane serine/threonine kinases, type I and II 
receptors (TǃRI and TǃRII). TǃRII transphosphorylates TǃRI, activating its kinase function 
to exert its signalling effects. Activated TǃRI phosphorylates the intracellular proteins 
SMAD 2 and 3 which then associate with SMAD 4, translocating to the nucleus where the 
complex interacts with other transcriptional co-activators and co-repressors to regulate 
expression of several genes (Onder et al., 2008). This type of signalling that depends on 
SMAD, up-regulates the expression of many transcription factors such as SNAIL1, SNAIL2, 
TWIST, and members of the ZFH family, ZEB1 and ZEB2 (Sarrio et al., 2008; Vandewalle et 
al., 2005; Yang et al., 2004) that are considered to be primary transcriptional inducers of 
EMT. TGFǃ can also phosphorylate certain cytoplasmic proteins regulating cell polarity and 
tight junction formation. These include RAS/MAPK (Xue et al., 2003), integrin ǃ-1 (Blanco et 
al., 2002), integrin-linked kinase (Hartwell et al., 2006), p38 MAPK (Mani et al., 2007), RHOA 
kinase (ROCK) (Moody et al., 2005), PI3K (Martin et al., 2003), JAGGED1/NOTCH (Come et 
al., 2006), SARA (Laffin et al., 2008), NFKB (Lester et al., 2007), PAR6 (Berx et al., 2001; Storci 
et al., 2008), pAR66A and ERK (Wu et al., 2009). Furthermore, EMT induced by the 
oncogenic stimulation by RAS and/or RAF activation in mammary, kidney and skin 
epithelial tissue was found to depend almost completely on TGF-ǃ signaling (Moustakas 
and Heldin, 2009). TGFǃ can also induce the activation of other signalling pathways that 
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might participate in initiation of EMT such as the WNT and NOTCH pathways (Polyak and 
Weinberg, 2009). Figure 4 illustrates the major events that are thought to be critical in the 
trans-differentiation of epithelial cells.  
4.2 AXL 
As mentioned earlier, receptor tyrosine kinase activity is altered in breast cancer and is 
considered to be an important factor in endocrine resistance. These molecules are also 
implicated in EMT since they already play a pivotal role in embryogenesis. One interesting 
member of the TAM (Tyro-AXL-MER) receptor tyrosine kinases is AXL which exerts diverse 
effects in regulating cellular responses that include cell proliferation, cell survival, 
migration, autophagy, angiogenesis, natural killer cell differentiation and platelet 
aggregation (Linger et al., 2008). AXL was reported to be associated with EMT since it is 
activated in many signal transduction pathways including AKT, MAPK, NFKB, and STAT. 
(Hafizi et al., 2006). Furthermore, AXL expression alone is considered as a predictive marker 
for poor overall patient survival. It has also been reported that elevated AXL levels are 
needed for maintaining breast cancer invasiveness, growth in foreign microenvironments 
and metastatic potential. Endocrine-resistant breast cancer cells show highly elevated 
expression of AXL (Al Saleh et al., 2010).  
4.3 E-cadherin and its transcriptional repressors 
E-cadherin is a critical switch in EMT during early embryonic development. Its down-
regulation in epithelial cells triggers acquisition of a fibroblastic phenotype, dissociation 
from the epithelium sheets and migration, vital steps in gastrulation, neural crest 
formation and organ development (Thiery, 2003). E-cadherin expression is often lost in 
aggressive breast cancers acquiring EMT which would result in the disassembly of inter-
cellular adhesion complexes, loosening contacts between neighbouring epithelial cells and 
thus disrupting the overall tissue architecture. E-cadherin loss also causes the liberation of 
ǃ-catenin to the nucleus and its subsequent activation of WNT signalling of other EMT 
inducers as described above. Furthermore, E-cadherin loss mediates EMT through the 
induction of its own transcriptional repressors, SNAIL, TWIST and ZEB1 (EF1), in a feed-
forward loop that sustains E-cadherin repression and potentiates EMT (Onder et al., 2008). 
An interesting connection between endocrine resistance and EMT is established through the 
connection between SNAIL, E-cadherin and metastasis-associated protein 3 (MTA3). MTA3, 
which is directly activated by ER, is a repressor of SNAIL, thereby also repressing EMT (Al 
Saleh et al., 2011). We have recently shown that down-regulation of ER in MCF7 cells leads 
to a reduction in both MTA1 and MTA3 and a concurrent rise in SNAIL2 (Al Saleh et al., 
2011a). 
Reduction of E-cadherin expression correlates with poor differentiation, invasiveness, 
aggressive metastatic behaviour, and an unfavourable prognosis (Berx et al., 2001; Wheelock 
et al., 2003); experimental knockdown of E-cadherin is sufficient to establish metastasis but 
not fully reverse EMT by itself. Interestingly, the down regulated expression of E-cadherin 
during EMT is a reversible process that arises through hypermethylation of the E-cadherin 
promoter or transcriptional repression although many lobular breast cancers appear to have 
lost the expression of E-cadherin through inactivating mutations and loss of heterozygosity 
(Berx et al, 2001).  
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Fig. 4. Transduction pathways and effectors contributing to processes leading to EMT. A 
variety of growth factors (EGF, TGFǂ, IGFI, II, PDGF, HGF, FGF) binding to receptor 
tyrosine kinases (RTK) activate the central RAS pathway to promote transcription of SNAIL 
through the RAF/MAPK, the PI3K/AKT/NFKB or the SRC/LIV pathways. AKT, as well as 
WNTs acting through the FRIZZLED receptor, promote inhibition of GSK3 through DSH to 
promote re-localisation of ǃ-catenin and generate TCF/LEF that also increases SNAIL. 
DELTA/JAGGED signalling through NOTCH also increases SNAIL via CSL as well as 
TWIST through HIF1. TGFǃ signals through its receptor to increase SMAD family members 
that co-operatively promote both SNAIL as well as SIP1/ZEB2. It also acts through PAR6 to 
up-regulate the ubiquitin ligase SMURF that degrades RHO which is a key promoter of tight 
junctions, The transcriptional repressors SNAIL, TWIST, GSC, ZEB1,2 and TFC/LEF 
effectively down-regulate E-cadherin and associated molecules, which leads to loss of cell 
adhesion, permitting cell scattering, cellular motility and invasion through the action of up-
regulated proteases. Not shown here, for clarity, is HEDGEHOG signalling which through 
GLI integrates with the RTK and WNT pathways to up-regulate SNAIL family members 
Evidence for the interactions illustrated is summarised in excellent reviews by Huber et al., 
2005; Moustakes & Heldin, 2007 and Sabbah et al., 2008 and references therein. 
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The appearance of another mesenchymal marker, N-cadherin (CDH12) and/or cadherin-11 
(CDH11), in a process termed ‘cadherin switching’, is also a well documented event in EMT 
(Gjerdrum et al., 2010; Sarrio et al., 2008; Sphyris and Mani, 2009; Wheelock et al., 2008). The 
expression of these mesenchymal markers during EMT is induced by SNAIL, ZEB2/SIP1 
and SNAIL2 (Cano et al., 2000; Sarrio et al., 2008; Vandewalle et al., 2005). N-cadherin is 
reported to be highly expressed in invasive and metastatic human breast cancer cell lines 
and tumours and to correlate with aggressive clinical behaviour. Nevertheless, N-cadherin 
expression can be triggered in E-cadherin expressing cells and it could in fact cause EMT, 
impacting on their epithelial phenotype, suggesting a dominating role for this cadherin over 
the other, possibly in synergy with FGF2 (Hazan et al., 2000, 2004). MCF7 cells that have 
acquired endocrine independence through induced loss of ER expression also display 
cadherin switching which is accompanied by increased motility, F-actin cytoskeletal 
rearrangement and the loss of cellular adhesion molecules. It is suggested that endocrine 
resistance is a major event influencing the cells to move and invade into the surrounding 
tissues (Al Saleh, 2010; Al Saleh et al., 2011a).  
4.4 Vimentin 
A marker that is commonly used to characterise EMT is vimentin, a component of type III 
intermediate filaments and the archetypal mesenchymal marker (Trimboli et al., 2008). 
Elevated vimentin expression correlates well with increased cell migration, invasion and 
EMT induction in several breast cancer cell lines (Al Saleh, 2010; Al Saleh et al., 2011a; Gilles 
et al., 2003) in co-ordination with other mesenchymal markers such as tenascin C (Dandachi 
et al., 2001; Polette et al., 2007), which has been associated with over-expressed ERBB2 and 
down-regulated ER. The molecular events triggering vimentin expression during EMT are 
less well delineated in comparision to the mechanisms inducing E-cadherin down-
regulation. The expression of vimentin is considered to be a late occurrence in EMT in a 
temporal sequence of genetic events starting from loss of epithelial markers followed by 
appearance of mesenchymal markers (Polette et al., 2007). Direct activation of vimentin 
expression in human breast tumour cells (Gilles et al., 2003) by ǃ-catenin/T-cell 
factor/lymphocyte enhancer factor-1 is consistent with the activation of ǃ-catenin as a 
downstream event from consequential loss of E-cadherin. The indirect promotion of 
vimentin expression by ZEB2/SIP1 during EMT in a ǃ-catenin-independent manner 
(Bindels et al., 2006) suggests the existence of some trans-activators driving EMT which are 
associated with vimentin expression. 
4.5 Matrix metalloproteinases and lipocalin 
In order for cancer cells to metastasise, they need to penetrate into and through the 
extracellular matrix (ECM). This process is facilitated by the activity of matrix 
metalloproteinases (MMPs). A family of more than 28 MMPs have been reported to be up-
regulated in nearly every tumour type and are closely involved in cancer progression 
through cleavage and release of bioactive molecules that inhibit apoptosis and stimulate 
cancer invasion and metastasis. For example, treatment of cells with MMP-3 results in an 
increased expression of the activated splice variant RAC1b, elevating the levels of cellular 
reactive oxygen species which, in turn, lead to increased expression of SNAIL and EMT 
initiation (Orlichenko et al., 2008). An MMP-9 associated protein, Lipocalin2 (LCN2), was 
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also found to play a major role in cell regulation, proliferation, differentiation and regulation 
of EMT. It’s over-expression in human breast cancer cells can cause up-regulation of 
vimentin and fibronectin while E-cadherin is down regulated (Yang et al., 2009). 
Furthermore, LCN2 over-expression significantly increases cell motility and invasiveness in 
previously non-invasive MCF-7 cells. Interestingly, siRNA-mediated LCN2 silencing 
inhibited cell migration and development of the mesenchymal phenotype in aggressive 
breast cancer cells. It was also reported that reduced expression of ER and increased 
expression of SNAIL2 was correlated with LCN2 expression while over-expression of ER in 
LCN-2 expressing cells was able to reverse EMT and reduce SNAIL2 expression, suggesting 
that ER negatively regulates LCN2-induced EMT (Yang et al, 2009). 
4.6 Hypoxia 
An interesting physiological mechanism that can cause EMT is hypoxia. It has been reported 
that tumour progression and metastasis is promoted by the stabilisation of the hypoxia-
inducible factor-1ǂ (HIF-1ǂ). This transcription factor was shown to be associated with 
TWIST in inducing both EMT and tumour metastasis by hypoxia or over-expression of the 
former. Furthermore, the expression of TWIST was found to be regulated by HIF-1 binding 
to the hypoxia-response element (HRE) in the TWIST proximal promoter and is associated 
with it in inducing EMT or metastasis (Yang et al, 2008). Interestingly, the HIF-1ǂ null mice 
phenotype resembles TWIST deficient mice. In addition, patients with head and neck cancer 
whose tumours co-express TWIST and HIF-1 had very poor prognosis suggesting a major 
role for these two genes in regulating EMT.  
4.7 HOX genes 
Another important set of genes in regulating EMT is the homeobox (HOX) gene family, 
master players in regulating embryonic development and maintaining homeostasis through 
strictly regulated expression in various tissues and organs during adult life. Several studies 
have demonstrated the association of HOX genes in the pathogenesis of multiple cancers. 
For example, HOXA7 and HOXD13 have been associated with lung cancer (Lechner et al., 
2001), HOXC4 and HOXC8 in prostate cancer (Miller et al., 2003), HOXB7 in ovarian cancer 
(Naora et al, 2001) and HOXA10 in endometrial cancer (Yoshida et al., 2006). In one study 
60% of their breast cancers had no HOXA5 expression (Raman et al., 2000) which causes 
p53-dependent apoptosis. HOXA5 was reported to cause cell death through the activation of 
the caspase pathways in HS578T cells expressing mutant p53 (Chen et al., 2004). HOXD10 
was extensively reduced as malignancy increased in epithelial cells, and restoring its 
expression in MDA-MB-231 could significantly reduce the migration capacity of these 
highly aggressive cells (Carrio et al., 2005). HOXB13 over-expression was associated with 
increased MCF10A cell motility and invasion in vitro, while its ratio to interleukin-17ǃ 
receptor was predictive of tumour recurrence during adjuvant tamoxifen monotherapy. 
HOXB7 is involved in tissue remodeling of the normal mammary gland (Ma et al., 2004) and 
is expressed at higher levels in metastatic breast tumours (Care et al., 1998, 2001). 
Furthermore, regulation of the expression of several growth and angiogenic factors, 
including basic FGF, VEGF, IL8, ANG1, ANG2, and MMP9 in SKBR3 breast cancer cells, 
depends on the over-expressed levels of HOXB7 which can result in the formation of 
vascularised tumours when grown as xenografts in nude mice. HOXB9 like HOXB7 can lead 
to increased cell motility and EMT (Hayashida et al., 2010).  
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4.8 NOTCH 
DELTA/JAGGED acting through the NOTCH pathway are implicated in both cell fate in 
the normal human mammary gland (Raouf et al., 2008) and regulation of cancer stem cells 
(CSCs) in both ductal carcinoma in situ and in invasive carcinoma of the breast (Dontu et al., 
2004; Stylianou et al., 2006). This pathway is known to be transcriptionally induced by 
TGFǃ/SMAD signalling and contributes to EMT (Zavadil et al., 2004). This pathway is cell 
type specific and can be either oncogenic through activation of the NKFB pathway or it can 
be tumour suppressive. Wang et al., (2006) provided evidence demonstrating that NOTCH 
receptor signalling regulates SNAIL 1 and 2, ZEB1 and vimentin. 
4.9 WNT 
The WNT signalling pathway mediates several vital processes such as cell proliferation, 
migration, differentiation, adhesion and death (Vincan et al., 2008). In addition, this 
pathway can promote migration and EMT in breast cancer cells through the stabilisation or 
increased expression of SNAIL1 and 2 and TWIST (Onder et al., 2008; Vogelstein et al., 
2004). SNAIL has been implicated in regulating WNT-1-induced EMT in MCF-7 cells. 
Furthermore, WNT signalling can also lead to the translocation of ǃ-catenin to the nucleus 
where it can drive the expression of several EMT inducing transcription factors through the 
WNT induced inhibition of glycogen synthase kinase-3ǃ (GSK3ǃ)-mediated 
phosphorylation. However, ǃ-catenin alone usually is not enough to induce EMT although 
in colorectal cancer WNT is indeed a silencer of its negative regulators SOX17 (Zhang et al., 
2008), SFRPS18, 19 and DKK1 (Aguilera et al., 2006). Interestingly, both SFRP1 and DKK1 
are frequently silenced by methylation in breast cancer. 
4.10 miRNA 
It is well established that non-protein coding micro (mi) RNAs play a significant role in 
regulation of gene expression and cellular protein levels. They are now also being 
increasingly recognised as major regulators of EMT and metastasis, specifically the miR-200 
family (miR-200a, miR-200b, miR-200c, miR-141, miR-429 and miR-205 (Gregory et al, 2008; 
Park et al., 2008). Members from the miR-200 family and miR-205 are associated with 
increased expression of E-cadherin and decreased vimentin. In addition, these miRNAs also 
target the expression of ZEB1 and ZEB2, the E-cadherin transcriptional repressors. 
Expression levels of miR-205 and of some members of the miR-200 family were also found 
to vary inversely with vimentin expression in primary serous papillary carcinomas of the 
ovary (Park et al., 2008). In another study, EMT was induced through either TGFǃ or the 
tyrosine phosphatase pEZ in Madin–Darby canine kidney (MDCK) cells. The levels of both 
miR-205 and miR-200 family members was down-regulated after EMT induction while their 
ectopic expression induced MET (Gregory et al., 2008).  
One way that natural antisense transcripts can play a major role in EMT is by targeting the 
regulation of ZEB2 expression. This was documented when EMT was induced in a human 
colorectal cancer cell line by SNAIL. ZEB2 levels were found to be directly increased after 
EMT initiation which was explained as the result of the action of a natural antisense 
transcript that prevented the splicing of a large intron in the 5′ untranslated region (UTR) 
that contains an internal ribosomal entry site which lowers ZEB2 levels in epithelial cells 
through the inhibition of ribosome scanning. During EMT activation, the antisense 
transcript levels are increased. They bind to the 5’UTR and inhibit splicing, preserving the 
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internal ribosomal entry site sequence and thereby increasing the translational efficiency of 
ZEB2 which then directly inhibits E-cadherin expression, maintaining an EMT state (Beltran 
et al., 2008). 
Although these RNA molecules are associated with the regulation of EMT and MET, other 
miRNAs such as miR-10b are reportedly associated with metastasis and invasion. It inhibits 
HOX10 translation while increasing RHOC when induced by TWIST (Ma et al., 2007). 
Another miRNA that seems to increase the metastatic potential of cancer cells is miR-29a; 
up-regulated in a mesenchymal metastatic RASXT mammary cell line compared to 
epithelial EpRas cells. In addition, over-expression of miR-29a suppresses expression of 
tristetraprolin, a regulator of epithelial polarity and metastasis, and leads to EMT and 
metastasis through RAS signalling. This correlates with data from breast cancer patients 
showing enhanced miR-29a and reduced tristetraprolin levels (Gebeshuber et al., 2009). In 
contrast to miR-10b, miR-335 was found to be a suppressor of invasion and metastasis 
through modulation of the expression of the ‘six gene signature’ set: COL1A1, MERTK, 
PLCB1, PTPRN2, TNC and SOX4 which are considered predictive markers of metastasis and 
invasion. miR-335 was also reported to suppress invasion and metastasis in MDAMB231, a 
highly metastatic and invasive ER-ve breast cancer cell line (Tavazoie et al., 2008).  
4.11 Epithelial to mesenchymal transition and breast cancer stem cells 
An interesting idea that has emerged recently suggests the possibility that cancer cells 
undergoing EMT acquire stem cell-like characteristics. The breast cancer stem cell (BCSCs) 
hypothesis contends that breast cancer is derived from a single tumour initiating cell with 
stem cell-like properties. 
BCSCs are characterized as CD24−/low and CD44+ cells which are associated with basal 
subtype breast cancer. It was first reported by Al-Hajj et al., (2003) when they showed that a 
CD44+/CD24−/low sub-population of breast cancer cells could produce tumours in a 
xenograft model more effectively. These cells are regarded as the ‘metastatic component’ of 
the cancer, particularly in breast neoplasms as they are the only subset of cells with potential 
to initiate new tumour growth. This was further supported by analysis of genetic profiles of 
CD44+ breast cancer cells which showed enrichment with stem-cell markers and displayed 
activated TGFǃ signalling with lung metastasis and poor clinical outcomes (Sheridan et al., 
2006; Shipitsin et al., 2007). Furthermore, it has been reported that metaplastic and claudin-
low breast cancers are enriched with markers of EMT and display stem cell characteristics 
suggesting that cancer cells undergoing EMT exhibit stem cell-like characteristics (Prat et al., 
2010). In addition to that, inducing EMT in immortalized human mammary epithelial cells 
with either TGFǃ, SNAIL1 and TWIST confers stem cell characteristics with increased 
formation of mammospheres in three dimensional culture and ductal outgrowths in 
xenotransplants (Mani et al., 2008; Morel et al, 2008). Interestingly, BCSCs isolated from 
primary tumors and normal breast tissue showed an increased expression of the 
mesenchymal markers TWIST1 and 2, FOXC2, SNAIL1, ZEB2, vimentin and fibronectin 
while epithelial cells (which are CD44-/CD24+) isolated from differentiated carcinoma do 
not (Mani et al., 2008). Furthermore, hypoxia-induced SNAIL2 expression has also been 
associated with acquisition of a basal-like breast cancer phenotype with high levels of the 
stem cell regulatory genes CD133 and BMI1 (Storci et al., 2008). Inhibition of WNT 
signalling through LRP6 was found to reduce stem cell-like properties and cause EMT 
reversal, restoration of the epithelial phenotype, and suppression of SNAIL2 and TWIST 
expression (DiMeo et al., 2009) in a mouse model of breast cancer metastasis to the lung.  
www.intechopen.com
 Breast Cancer – Focusing Tumor Microenvironment, Stem Cells and Metastasis 
 
468 
It has also been reported that a CD24−/low /CD44+ in vivo tumour out- growth which is 
enriched with EMT markers results from CD8 T-cell-mediated immune response to 
epithelial breast cancer which would develop characteristics of aggressive carcinomas 
including potent tumourigenicity, ability to re-establish an epithelial tumour, and enhanced 
resistance to drugs and radiation (Sheridan et al., 2006; Santisteban et al., 2009). Moreover, 
breast cancer cells disseminated into the circulation and bone marrow are enriched with 
CD44+CD24– antigen phenotype (Balic et al., 2006)  
EMT induction may be a contributory factor to the decreased efficacy of chemotherapy in 
breast (Cheng et al., 2007), colorectal (Yang et al., 2006) and ovarian cancer (Kajiyama et 
al., 2006) while introduction of TWIST into breast cancer cells has been shown to induce 
paclitaxel resistance. In addition, AKT2 expression, which was amplified in breast cancer 
has also been correlated with acquired paclitaxel resistance (Cheng et al., 
2007). Interestingly, acquisition of enhanced EGFR/ERBB2 signalling in ER+ breast cancer 
with tamoxifen resistance has been suggested to result from the selection of a more stem 
cell-like phenotype. EGFR expression is seen in stem cells of the normal mammary gland 
in both mice and humans (Asselin-Labat et al., 2006; Hebbard et al., 2000) whilst ER is 
predominantly expressed in the more differentiated luminal cells (Hebbard et al., 2000; 
Shipitsin et al., 2007). Furthermore, the EGFR pathway is also activated in CSCs of DCIS 
of the breast and there is emerging evidence for a role of the ERBB2 pathway in the 
function of CSCs. Expression of ERBB2 and presence of ALDH1+ CSCs was positively 
correlated in one series of 491 breast cancer patients (Ginestier et al., 2007). The CSC 
populations of four ERBB2+ breast cancer cell lines have been shown to express more 
ERBB2 mRNA and protein in comparison to the non-CSC population. Furthermore, 
trastuzumab was also shown to reduce mammosphere-forming ability and 
tumourigenicity on serial xenotransplantation (Magnifico et al., 2009). Interestingly, 
ERBB2+ tumours that received treatment with lapatinib showed decreased EMT related 
genes in comparison to CD24low/-/CD44+ post treatment tissues from patients that 
received standard anthracycline-taxane chemotherapy. In addition, the Ǆ secretase 
inhibitor DAPT or a NOTCH 4 neutralizing antibody significantly reduced mammosphere 
formation in DCIS. NOTCH pathway antagonism has been reported to enhance the 
reduction of mammosphere formation in ERBB2 over-expressing cell lines induced by 
trastuzumab (Magnifico et al, 2009). 
Colorectal and lung tumours undergoing EMT display decreased sensitivity to EGFR kinase 
inhibitors, possibly by the activation of downstream targets PI3K and AKT (Barr et al., 2008). 
In breast cancer, CD44+/CD24−/low CSCs acquire resistance against the chemotherapeutic 
agents docetaxel, doxorubicin and cyclophosphamide (Li et al., 2008). Furthermore, a 
proportion of CD44+/CD24−/low cells increase in breast cancer patients following treatment 
with these anti-cancer drugs suggesting that breast cancer cells may acquire resistance to 
both conventional and targeted therapies upon conversion to a mesenchymal-like 
phenotype. This in turn would suggest that any EMT inducing factors such as TWIST and 
ERBB2 are crucial players in inducing cancer stem cells. 
An analysis of a panel of breast cancer cell lines of luminal, intermediate and basal 
phenotypes showed a significant increase in the fraction of CSCs (CD44+/CD24low/-/ESA+ ) 
in basal type breast cancers compared to hormone-sensitive luminal cancers (Fillmore & 
Kuperwasser, 2008). In addition, the number of CSCs and cell line tumourigenicity in in vivo 
models was correlated positively (Fillmore et al., 2008).  
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A functionally redundant ER in endocrine-resistant breast cancer might promote a more 
mesenchymal stem-cell-like phenotype based on the observation that ER negatively 
regulates the expression of the key EMT transcription factors including SNAIL1 and 
SNAIL2 (Dhasarathy et al., 2007; Ye et al., 2008). Furthermore, tamoxifen resistant MCF7 
cells have been reported to show an enhanced mammosphere formation capacity in 
comparison to the tamoxifen sensitive cells which suggests an increased CSC fraction (Storci 
et al., 2008). EMT may facilitate the generation of CSCs with mesenchymal and self-renewal 
properties necessary for dissemination and initiation of metastasis. (Hollier et al., 2009; Mani 
et al, 2008). An immunohistochemical analysis of 479 invasive breast carcinomas showed a 
high expression of the EMT-induced markers vimentin, ǂ-smooth muscle actin, N-cadherin, 
CDH1, SPARC, laminin and fascin, in comparison to the low expression of E-cadherin in 
these CD44+/CD24– basal-like breast tumours. These tumours have the ability to form 
distant metastases hence exhibiting a worse prognosis (Perou et al., 2000; Sorlie et al., 2001). 
In a study on 117 samples of primary invasive breast carcinomas, nuclear staining of the 
EMT inducing transcription factor FOXC2 showed a significant correlation with 
CD44+CD24– basal-like subtypes ( Mani et al., 2007). Another study on 226 blood samples 
from 39 patients with metastatic breast cancer showed that the majority of the circulating 
tumour cells (CTCs) exhibited EMT and CSC characteristics (Aktas et al., 2009). CTCs were 
present in 69 of 226 (31%) blood samples taken from patients with metastatic breast cancer 
to investigate the expression of TWIST, AKT2, and PI3Kǂ and ALDH1 which is considered 
to be a stem cell marker. In the CTC-positive group, 62% were positive for the EMT markers 
and 69% for ALDH1, while in the CTC-negative group the proportions were 7 and 14%, 
respectively (Aktas et al., 2009). The CTCs have also been shown to have a reduced 
expression of epithelial-specific cytokeratins (Pantel et al., 2008). Interestingly, disseminated 
tumour cells (DTCs) over-expressed TWIST. Assessment of occurrence of bone marrow 
metastases indicated that TWIST+ cells were present prior to chemotherapy and this was 
significantly associated with relapse (Watson et al., 2007). 
EMT undergoing CTCs have also been shown to resist apoptosis. One study reported that 
following the induction of EMT by TGFǃ in the EpH-4 and nMuMG murine mammary 
epithelial cell lines, they tended to acquire resistance to ultraviolet light induced apoptosis 
(Robson et al., 2006). Likewise, down regulation of the expression of LET-7 miRNA in breast 
cancer cell lines increased their metastatic potential and the resistance to therapy, in 
association with the acquisition of stem cell characteristics and EMT-associated gene 
expression profiles (Yu et al., 2007). Furthermore, the factors that can induce a full EMT; 
TGFǃ, WNT, HEDGEHOG, NOTCH, and RAS signaling pathways, are all considered to be 
involved in the induction and maintenance of stem cell niches (Fuxe et al., 2010). There is 
however some data showing that TGFǃ stimulation of transformed human breast epithelial 
cells can result in the loss of stem cell-like properties including the ability to form 
mammospheres (Tang et al., 2007). 
5. Endocrine resistance and EMT 
It is becoming increasingly apparent that acquired endocrine resistance is a multi-factorial 
stepwise progression that can be triggered through a number of distinct pathways, that in 
vitro, can be manipulated. Whether it is the actual loss of ER due to transcriptional or 
translational down-regulation, or functional redundancy of ER (which seems to be the more 
frequent occurrence in vivo), either scenario would have the same end result in terms of 
www.intechopen.com
 Breast Cancer – Focusing Tumor Microenvironment, Stem Cells and Metastasis 
 
470 
independence from estrogen. It is therefore pertinent to ask what happens to a cell that 
experiences loss of ER. As described in preceding sections this issue has been addressed by 
various cell models that have been made endocrine resistant by exposure to antiestrogens or 
by deprivation of estradiol, but rarely by the direct prevention of ER synthesis.  
We have explored this avenue by modifying MCF7 cells by transfection with shRNA 
generating plasmids targeting the ER mRNA (Al Azmi, 2006; Luqmani et al., 2009; Al Saleh 
et al., 2011a). As expected, stably transfected cell lines with constitutive reduction of ER 
(termed pII) exhibit a loss of response to either estradiol or tamoxifen/fulvestrant and 
hypersensitivity to EGF and IGF1 (Salloum, 2010). There is reduction in the classical ER-
regulated markers such as pS2, cathepsin D, PR and PRLR. Like the tumour-derived 
naturally ER-ve MDAMB231 cell line, these (acquired) endocrine resistant cells show 
increased motility and ability to invade simulated components of the ECM mimicking the 
behaviour of aggressive ER-ve/EGFR+ve tumours. Both of these activities as well as cellular 
proliferation are reduced by various tyrosine kinase inhibitors that are known to block, in 
particular, EGFR and VEGFR phosphorylation (Al Saleh, 2010) supporting the data 
mentioned in preceding sections. However, the most striking features of pII cells was 
initially noted in their morphological appearance (see Fig 3), assuming a more elongated 
spindly shape and failure to form the compact colonies characteristic of MCF7 cells, with re-
arrangement of the actin cytoskeleton giving rise to increased incidence of lamellipodia and 
microspikes, features closely associated with cellular motility (Parker et al., 2002).  
Microarray analysis confirmed that pII cells had assumed a phenotype that is generally seen 
for mesenchymal cells, with transcriptional loss of genes normally associated with epithelial 
cells. Lack of colony formation can be explained by loss of E-cadherin and many other 
factors responsible for normal cell-cell adhesion including catenins, laminin, type IV 
collagen, desmogleins, desmocollins, occludins, connexion 2b claudins and MUC1. 
Likewise, archetypical epithelial components such as keratins 8, 18 and 19 and tissue 
inhibitors of metallo-proteinases are all reduced. On the other hand, we observed an 
increased expression of mesenchymal markers such as N cadherin, vimentin, fibronectin, 
integrins ǃ4 and ǂ5, tenascin, SPARC, PLAU, VEGF, CD68, FSP1/S100A4, LCN2 and 
various metalloproteinases In short, we are seeing all the hallmarks of cells undergoing EMT 
with acquisition of the phenotype characterising the group of basal-like ‘claudin low’ 
tumours such as the triple negative (ER-ve, PR-ve, ERBB2-ve) metaplastic tumours 
described by Hennessy et al., (2009). A similar conclusion was reached by Gadalla et al., 
(2005) who observed an EMT-like transition with loss of E-cadherin and reduction in CD24 
induced by ER silencing. However, they did not observe the increase in CD44 that we and 
others have widely reported. 
An interesting molecule whose expression was found to be substantially repressed in our pII 
cells (Al Saleh et al., 2011a) is GATA3, a zinc finger transcription factor that plays an 
important role as a regulator of mammary gland formation and development (Kouros-Mehr 
et al., 2008) and has been implicated in both EMT and breast cancer metastasis. GATA3 is a 
positive transcriptional regulator of ER expression whilst simultaneously itself being a 
target gene for the ER complex. Its expression has been linked to favourable outcome of 
endocrine therapy (Parikh et al., 2005). Several studies have shown association of GATA3 
with ER+ tumours (eg, Mehra et al., 2005). Yan et al., (2010) recently demonstrated that not 
only was GATA3 expression abolished in ER-ve cell lines but also correlated with E-
cadherin. siRNA-induced silencing of GATA3 resulted in fibroblastic-like transformation of 
MCF7 cells. On the other hand, restoration of GATA3 expression in ER-ve cells led to 
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renewal of epithelial characteristics as typified by increased levels of E-cadherin and 
decrease of N-cadherin, vimentin and MMP9 with parallel reduction of tumour forming 
capacity of MDAMB231 cells injected into xenografted mice. These studies elegantly support 
the notion that ER regulated events is intimately involved in the same processes that lead to 
EMT and very crucially, that these events are reversible.  
Another significant group of genes variously implicated in EMT that is elevated in pII cells 
is included in the ‘24 gene signature’ of genes proposed as predictive of invasiveness 
(Zajchowski et al., 2001): integrin, TIMP-2 and TIMP-3, MT1-MMP, PAI-1, 
Osteonectin/SPARC, thrombospondin-1, collagen (VI) ǂ1 and collagen (I) ǂ2. pII also 
display the ‘9 gene signature’ of down-regulated or low expressing genes (E-cadherin, 
CLDN7, CRB3, KRT8, TACSTD1, IRF6, SPINT2, MAL2 and MARVELD3) that was found by 
Katz et al., (2011) to be common between their C35 transfected cells and claudin-low 
tumours. Evidence that the latter represent EMT is now substantial and supported by in 
vitro observations (Prat et al., 2010; Taube et al., 2010).  
Substantial reduction in ER expression has been observed in modified MCF7 sub-lines 
resistant to the mitotic inhibitors paclitaxel and docetaxel and the anthracycline doxorubicin 
(Iseri et al., 2011). Microarray analysis showed up-regulation of SNAIL2, CDH2, VIM, 
CLDN1, CLDN11, EGFR, FGFR1, SMAD3 and TGFBR2 and down-regulation of E-cadherin, 
OCLN, CLDN3, CLDN4, and CLDN7. This data bears remarkable resemblance to the profile 
for pII cells with the common denominator being loss of ER. 
This brings us finally to the group of transcriptional repressors that have been coined as the 
‘mediators of EMT’ and discussed above, so far a relatively smaller group that unify a much 
larger and diverse array of signalling molecules involved in their regulation. Of the key 
factors identified in cadherin switching, ZEB1, ZEB2/SIP1 and SNAIL2 (Onder et al, 2008) 
are all significantly elevated in our endocrine resistant pII cells. These observations lead us 
to conclude that there is a high degree of synonimity between endocrine resistance and 
EMT, both effected by functional loss of ER and both resulting in increased propensity for 
tumour dissemination through the actions of a common set of mediators. The repression of 
SNAIL by the ER dependent MTA3 (Fujita et al., 2003), a subunit of the Mi-2/NuRD histone 
deacetylase complex, which could well be regarded, among others, as a guardian of the 
epithelial phenotype (?) may be worthy of further attention. Interestingly, another family 
member, MTA1, is described as a potent inhibitor of nuclear ER function through 
cytoplasmic sequestration of the receptor and this may provide an explanation for resistance 
in ER+ cells as MTA1 would indirectly reduce the levels of MTA3 thereby relieving SNAIL 
repression.  
There have also been intriguing suggestions regarding the origin of the mesenchymal-like 
cells, with the attractive view of these as a possibly slow growing pre-existing CSC sub-
population within the tumour (Lim et al., 2010; May et al., 2011). In such a scenario there is 
no induced EMT as such, but a gradual emergence of a group of cells already bearing these 
properties, to become the dominant group. Similar ideas have often been suggested to 
explain the re-emergence of ‘drug–regressed’ tumours as an expansion of a pre-existing 
intrinsically resistant cell population once the sensitive cells have been eliminated. 
However, attractive as this may be, in the alternative scheme elaborated by May et al., (2011) 
there would be a reversion of such ‘MaSCs’ back to an epithelial phenotype at the site of 
metastatic growth in a reverse MET transition, which raises the question that If cells can 
undergo MET then why not EMT, and there is no necessity to postulate the existence of a 
priori mesenchymal cells. Moreover, the in vitro data demonstrates quite clearly that an 
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actual EMT transition does take place as the initial population of cells is relatively 
homogeneous with respect to being epithelial in nature. Most if not all of the cells in culture 
can simultaneously undergo EMT whereas it is very likely that only a very small fraction of 
cells in a tumour acquire all of the characteristics enabling them to undergo a full transition, 
which may be why such mesenchymal-like cells have not been routinely reported by 
pathologists (Thompson et al., 2008).  
6. Summary 
The persistent problem of drug resistance and in particular the therapeutic failure of 
endocrine agents presents serious therapeutic issues especially in view of the success of this 
type of intervention in a significantly large proportion of women with breast cancer. Many 
studies have focused on elucidating the mechanisms responsible for de novo and acquired 
independence from estrogen. Consensus of opinion favours the view that signaling 
pathways mediated through a variety of peptide growth factors is largely responsible for the 
aggressive proliferation of tumours that have ceased to depend upon the ER, although no 
single unifying or even major factor has been identified. Somewhat in parallel, the last few 
years have witnessed an increasing number of reports describing the relatively recently 
recognized phenomenon of EMT, highlighting its similarity to the events leading to tumour 
invasion and vascular dissemination. Many of the key mediators of EMT particularly the 
transcriptional repression of E-cadherin by SNAIL appear to be critical steps in tumour 
progression. The association of mesenchymal-like features such as cadherin switching, loss 
of adhesion proteins and CD24, increased vimentin and fibronectin, with ER-ve tumours, 
have been sporadically, almost anecdotally reported in the literature over the last decade or 
more. We have now found evidence to show that the acquisition of endocrine 
independence, due to induced ER loss, by previously ER+ breast cancer cells, is 
accompanied by all the hallmark features of EMT. Although it is still far from clear whether 
the two processes are occurring side by side or whether either is causal of the other, it seems 
reasonable to conclude that loss of ER can directly trigger EMT. It remains to be seen 
whether restoration of ER in the trans-differentiated cells can reverse EMT and allow the 
cells to regain estrogen dependence.  
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